Sectors
JANX
Janux Therapeutics, Inc.
15.77
6 x 15.75
2 x 15.78
bid
ask
-
0.49
3.01%
11:14 AM
timesize
| Ytd | 14.28% | |
| 1y | -40.22% |
15.56
day range
16.37
12.12
52 week range
35.34
| Open | 16.26 | Prev Close | 16.26 | Low | 15.56 | High | 16.37 | Mkt Cap | 991.61M |
| Vol | 191.74K | Avg Vol | 1.07M | EPS | -1.84 | P/E | -8.84 | Forward P/E | -6.08 |
| Beta | 2.52 | Short Ratio | 5.37 | Inst. Own | 102.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 14.71 | 200-d Avg | 17.20 | 1yr Est | 37.19 |
| Income Statement | |||
| Total Revenue | 3.73M | ||
| Revenues (USD) | 3.73M | ||
| Gross Profit | 3.73M | ||
| Operating Expenses | 37.95M | ||
| Research and Development Expense | 26.81M | ||
| Selling, General and Administrative Expense | 11.13M | ||
| Operating Income | -34.21M | ||
| Net Income | -24.36M | ||
| Net Income Common Stock | -24.36M | ||
| Net Income Common Stock (USD) | -24.36M | ||
| Consolidated Income | -24.36M | ||
| Earnings per Basic Share | -0.39 | ||
| Earnings per Basic Share (USD) | -0.39 | ||
| Earnings per Diluted Share | -0.39 | ||
| Earning Before Interest & Taxes (EBIT) | -24.36M | ||
| Earning Before Interest & Taxes (USD) | -24.36M | ||
| Weighted Average Shares | 62.67M | ||
| Weighted Average Shares Diluted | 62.67M | ||
| Balance Sheet | |||
| Cash and Equivalents | 52.64M | ||
| Cash and Equivalents (USD) | 52.64M | ||
| Investments | 904.56M | ||
| Investments Current | 904.56M | ||
| Trade and Non-Trade Receivables | 35.00M | ||
| Current Assets | 1.00B | ||
| Property, Plant & Equipment Net | 21.42M | ||
| Total Assets | 1.03B | ||
| Debt Current | 2.47M | ||
| Total Debt | 21.57M | ||
| Current Liabilities | 58.92M | ||
| Debt Non-Current | 19.10M | ||
| Total Liabilities | 86.69M | ||
| Accumulated Retained Earnings (Deficit) | -375.74M | ||
| Accumulated Other Comprehensive Income | 576.00K | ||
| Shareholders Equity | 941.54M | ||
| Shareholders Equity (USD) | 941.54M | ||
| Assets Non-Current | 26.18M | ||
| Total Debt (USD) | 21.57M | ||
| Deferred Revenue | 46.27M | ||
| Liabilities Non-Current | 27.78M | ||
| Trade and Non-Trade Payables | 3.38M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 469.00K | ||
| Net Cash Flow from Financing | 3.55M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -506.00K | ||
| Capital Expenditure | -273.00K | ||
| Issuance (Purchase) of Equity Shares | 3.55M | ||
| Net Cash Flow from Investing | 8.29M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 8.56M | ||
| Net Cash Flow from Operations | -12.34M | ||
| Share Based Compensation | 9.27M | ||